Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
Patricia Pérez, Guillermo Albericio, David Astorgano, Sara Flores, Cristina Sánchez-Corzo, Pedro J. Sánchez-Cordón, Joanna Luczkowiak, Rafael Delgado, José M. Casasnovas, Mariano Esteban, Juan García-Arriaza · 2023
Read Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates by Patricia Pérez, Guillermo Albericio, David Astorgano, Sara Flores, Cristina Sánchez-Corzo, Pedro J. Sánchez-Cordón, Joanna Luczkowiak, Rafael Delgado, José M. Casasnovas, Mariano Esteban, Juan García-Arriaza (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10754519.txt.
Description
Patricia Pérez and co-authors test in 2023 vaccine candidates against the beta variant of the virus that causes COVID-19. The vaccines use a harmless poxvirus shell to carry the variant's spike protein, tuned to hold its shape. Constant new variants keep forcing vaccine updates, so a fast platform matters.
Two shots fully protected gene-edited mice from a lethal beta challenge, clearing virus from lungs and easing lung damage. Antibodies rose against the original virus and five variants, and immune cells responded after a single nose dose. The results support taking these candidates toward human trials as variant-ready options.
Catalog record
| CREATOR | Patricia Pérez, Guillermo Albericio, David Astorgano, Sara Flores, Cristina Sánchez-Corzo, Pedro J. Sánchez-Cordón, Joanna Luczkowiak, Rafael Delgado, José M. Casasnovas, Mariano Esteban, Juan García-Arriaza |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |